Trilipix Use In Diabetics Might Be Restricted After FDA Panel Review Of ACCORD Data
This article was originally published in The Pink Sheet Daily
The agency's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 19 to consider how cardiovascular outcomes data on fenofibrate use in combination with simvastatin relate to the efficacy and safety of Trilipix, Abbott's second-generation fenofibrate product.
You may also be interested in...
Termination of the development program for dalcetrapib creates more doubt about the class of CETP inhibitors, long viewed with ambivalence. But important differences in how the drug works compared to rivals leaves room for some to hold out hope for CETP inhibition and the HDL hypothesis in general.
FDA follows its advisory committee’s recommendation and requires a post-marketing study of Abbott’s fibrate to determine whether combination use with a statin provides a cardiovascular benefit over statin monotherapy in high-risk patients.
Advisory committee says data inconclusive with subgroups and recommended another study to determine if there is increased risk in women and/or benefit for high TG, low HDL-C patients.